Michigan Team Validates Ion Oncomine Comprehensive Panel; Will Be Used in NCI Match Trial | GenomeWeb

NEW YORK (GenomeWeb) – Researchers at the University of Michigan and Thermo Fisher Scientific have developed and validated a comprehensive next-generation sequencing-based cancer panel on Thermo Fisher's Ion PGM.

The Oncomine Comprehensive Panel, which evaluates both DNA and RNA, is being used in the National Cancer Institute's Match trial, a basket trial that seeks to stratify patients into clinical trials based on their genomic profiles.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Sponsored by

This webinar will discuss a project that sought to understand the parent-of-origin epigenetic mechanisms that regulate seed development in plants, with a particular emphasis on differentiating the maternal or paternal origin of epigenetics marks.

Sponsored by

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.